CYP4F2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL154857	0.50	6/20
SCHEMBL46931	1.00	5/20
SCHEMBL154855	0.57	5/20
SCHEMBL158414	0.52	5/20
SCHEMBL220706	0.38	5/20
SCHEMBL63871	0.37	5/20
SCHEMBL186122	0.64	4/20
SCHEMBL77965	0.56	4/20
SCHEMBL241880	0.53	4/20
SCHEMBL46332	0.53	4/20
SCHEMBL40656	0.52	4/20
SCHEMBL96188	0.51	4/20
SCHEMBL154856	0.51	4/20
SCHEMBL186370	0.51	4/20
SCHEMBL187373	0.51	4/20
SCHEMBL20413	0.50	4/20
SCHEMBL77237	0.47	4/20
SCHEMBL127411	0.46	4/20
SCHEMBL242247	0.45	4/20
SCHEMBL168052	0.38	4/20

Clinical trials — most relevant to CYP4F2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
OPTImization of the Dose of tacroliMUS by Bayesian Prediction	PHASE4	COMPLETED
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians	PHASE4	UNKNOWN
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors	PHASE1	COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
The Study of Warfarin Maintenance Dose in Chinese Patients	nan	UNKNOWN
Pharmacogenetic Dosage Algorithm for Acenocoumarol	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	nan	COMPLETED
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant	nan	RECRUITING
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED
Individualized Antiretroviral Therapy	nan	COMPLETED
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients	nan	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder	nan	UNKNOWN
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen	nan	UNKNOWN
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP4F2 binder may also engage these)

Protein	Name	Similarity
CYP4F3	Cytochrome P450 4F3	1.000	landscape →
Q9EP75	—	1.000	Q9EP75 →
P33274	—	1.000	P33274 →
P51870	—	1.000	P51870 →
CYP4F8	Cytochrome P450 4F8	1.000	landscape →
Q99N16	—	1.000	Q99N16 →
P51869	—	1.000	P51869 →
Q3MID2	—	1.000	Q3MID2 →
CYP4F12	Cytochrome P450 4F12	0.999	landscape →
CYP4F11	Cytochrome P450 4F11	0.996	landscape →
Q64462	—	0.996	Q64462 →
P51871	—	0.994	P51871 →
P15128	—	0.994	P15128 →
Q6A152	—	0.993	Q6A152 →
Q6NT55	—	0.993	Q6NT55 →
Q9W011	—	0.992	Q9W011 →
A2RRT9	—	0.992	A2RRT9 →
Q6ZWL3	—	0.992	Q6ZWL3 →
CYP4X1	Cytochrome P450 4X1	0.992	landscape →
P15129	—	0.991	P15129 →
Q9GLL1	—	0.989	Q9GLL1 →
Q5RCN6	—	0.989	Q5RCN6 →
CYP4Z1	Cytochrome P450 4Z1	0.989	landscape →
P11714	—	0.988	P11714 →
P12938	—	0.987	P12938 →
Q9QUJ1	—	0.986	Q9QUJ1 →
P20817	—	0.986	P20817 →
CYP2R1	Vitamin D 25-hydroxylase (EC 1.14.14.24) (Cyt	0.986	landscape →
Q9QYG5	—	0.986	Q9QYG5 →
P30437	—	0.986	P30437 →